Mauritius vs Mayotte: Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology
Mauritius
0.8%
in 2024
Mayotte
0.8%
in 2024
Mauritius rank
37th
Mayotte rank
37th
Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology over time
- Mauritius
- Mayotte
How they compare
Mauritius currently reports 0.8% against 0.8% in Mayotte, a difference of 0.0%.
Across all 10 years both countries report, Mayotte has been ahead every year.
Mauritius ranks 37th and Mayotte ranks 37th of 215 countries.
Head to head by decade
| Decade | Mauritius | Mayotte | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 1.2% | 1.2% | 0.0% | — |
| 2020s | 0.8% | 0.8% | 0.0% | — |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence of hepatitis b surface antigen (hbsag), 2026 methodology, Mauritius or Mayotte?
- Mauritius, at 0.8% against 0.8% in Mayotte as of 2024.
- What is the difference in prevalence of hepatitis b surface antigen (hbsag), 2026 methodology between Mauritius and Mayotte?
- 0.0%, with Mauritius ahead.
- How many years of comparable data are there for Mauritius and Mayotte?
- 10 years are reported by both, from 2015 to 2024.
- How do Mauritius and Mayotte rank globally for prevalence of hepatitis b surface antigen (hbsag), 2026 methodology?
- Mauritius ranks 37th and Mayotte ranks 37th of 215 countries.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.